Endiya Partners has released its latest report, “India’s Biopharma Moment: Perspectives from DEMO Biotech,” highlighting an evolution underway in India’s biopharma landscape from a global leader in generics to a high-velocity, cost-effective hub for global biopharma innovation.
The report underscores that India is at an inflection point, driven by policy tailwinds, regulatory reforms, and the emergence of high quality clinical-stage assets receiving global validation. India’s unique "Recruitment Alpha" and ‘More Shots on Goal’ advantage positions it well to emerge as a global biopharma innovation hub amidst the rising demand for cost-efficient high quality R&D.
The global biopharma industry is undergoing a structural reset as R&D costs soar to $2.2 billion per asset and development cycles average 100 months. Driven by a shift toward complex modalities like gene therapies and mRNA, alongside a looming $300 billion patent cliff and geopolitical volatility, the demand for more cost-efficient, high-velocity R&D ecosystems is increasing.
Indian biotech startups benefit from a ‘Recruitment Alpha’, enrolling patients up to ten times faster and advancing drugs to Phase II with <$50 million, enabling 3–4x ‘More Shots on Goal’ compared to the west. However, gaps in pilot scale GMP infrastructure, late-stage funding, talent, and translational research remain.
Looking ahead, the report outlines four key pillars for growth: Blended Finance for derisking frontier science and enabling exits, building ‘industrial intelligence’, translational infrastructure and a dynamic regulatory architecture.
With sustained policy support and deeper ecosystem collaboration, India is well-positioned to emerge as a global hub for cost-efficient, high-quality biopharma innovation.
“This is a great time to be building biotech in India. With the global industry seeking high-velocity R&D and diversified supply chains, India offers a unique combination of clinical depth, technical talent, and cost-efficiency that allows us to solve the world's most complex medical challenges at a fraction of the traditional cost,” said Dr Vedha Sampathkumar, Endiya Partners.
